A program to provide regulatory support for investigator-initiated clinical research

Academic Medicine

Volumn 81, Issue 2, 2006, Pages 146-153

  Arbit, Harvey M ^a,b,d   Paller, Mark S ^a,c  

^a Academic Health Center   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH; FOOD AND DRUG ADMINISTRATION; HEALTH CENTER; HEALTH PROGRAM; MEDICAL LITERATURE; PRIORITY JOURNAL; REVIEW; UNITED STATES; ARTICLE; CLINICAL TRIAL; DOCUMENTATION; DRUG APPROVAL; DRUG SCREENING; GOVERNMENT REGULATION; HUMAN; LEGAL ASPECT; MEDICAL RECORD; METHODOLOGY; ORGANIZATION AND MANAGEMENT; PERSONNEL; PROGRAM DEVELOPMENT; SAFETY; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; CLINICAL TRIALS; DEVICE APPROVAL; DOCUMENTATION; DRUG EVALUATION; FORMS AND RECORDS CONTROL; GOVERNMENT REGULATION; HUMANS; INVESTIGATIONAL NEW DRUG APPLICATION; MINNESOTA; PROGRAM DEVELOPMENT; RESEARCH PERSONNEL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33645836520     PISSN: 10402446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001888-200602000-00009     Document Type: Review

References (23)

1. Pie charts showing FDA budget from the FY 2005 justification of estimates for appropriations 〈http://www.fda.gov/oc/oms/ofm/budget/2005/BIB/2005pie. htm〉. Accessed 24 October 2005. Food and Drug Administration, Rockville, MD, 2005.
2. 21 U.S.C. § § 321(g)(1), 321(p), 321(h) (2004).
3. 21 C.F.R. § 310.3(h) (2005).
4. 21 C.F.R. § 812.2(m) (2005).
5. 21 C.F.R. § 312.2(b)(1) (2005).
6. 21 C.F.R. § 812.2(b) (2005).
7. Guidance for Industry. Providing Regulatory Submissions in Electronic Format - General Considerations 〈http://www.fda.gov/cder/guidance/2867fnl. pdf〉. Accessed 24 October 2005. Food and Drug Administration, Rockville, MD, 1999.
8. 21 C.F.R. § § 312.23, 812.20 (2005).
9. IND Process and Review Procedures. Manual of Policies and Procedures 6030.1 〈http://www.fda.gov/cder/mapp/6030-1.pdf〉. Accessed 24 October 2005. Food and Drug Administration, Rockville, MD, 1998.
10. Guidance on IDE Policies and Procedures 〈http://www.fda.gov/cdrh/ ode/idepolcy.html〉. Accessed 24 October 2005. Food and Drug Administration, Rockville, MD, 1998.
11. Holobaugh, Patricia, chief, bioresearch monitoring branch, FDA/CBER/Office of Compliance and Biologics Quality. Personal communication, August 23, 2005.
12. FDA's Electronic Freedom of Information Reading Room - Warning Letters and Responses 〈http://www.fda.gov/foi/warning.htm〉. Accessed 24 October 2005. Food and Drug Administration, Rockville, MD, 2005.
13. 21 C.F.R. § 312.2(b)(1)(iii) (2005).
14. 21 C.F.R. § 812.3(m) (2005).
15. Policy 2.1.10 Reporting sponsor-investigator new drug applications (IND) or investigational device exemption (IDE) 〈http://www.fpd.finop.umn.edu/ groups/ppd/documents/policy/indidepol.cfm〉.Accessed 24 October 2005. University of Minnesota, Minneapolis, MN, 2003.
16. 21 C.F.R. § § 312.2, 812.2 (2005).
17. 21 C.F.R. § 312 Subpart D (2005).
18. Kolata G . Johns Hopkins admits Fault in Fatal Experiment. The New York Times. July 17, 2001:A16.
19. Form FDA 483 Inspectional Observations. Johns Hopkins Asthma & Allergy Clinic. J Diann Shaffer, Investigator. June 28, 2001 〈http://www.fda.gov/ora/frequent/483s/johnhopkins483.html〉. Accessed 24 October 2005. Food and Drug Administration, Rockville, MD, 2001.
20. Bren L. Human research reinstated at Johns Hopkins, with conditions. FDA Consumer Magazine. 2001 Sep-Oct;35(5):11.
21. Paller MS, Hostetler L, Dykhuis DA. Clinical trials at AHCs: the perspective of an academic clinical trials office. Acad Med. 2002;77(12 Pt 1):1201-6.
22. 21 C.F.R. § § 312.50, 312.53(d), 312.56(a) (2005).
23. Guidance for Industry. E6 Good Clinical Practice: Consolidated Guidance 〈http://www.fda.gov/cder/guidance/959fnl.pdf〉. Accessed 24 October 2005. Food and Drug Administration, Rockville, MD, 1996.